1.Kessler, RC, Walters, EE.Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. Depress Anxiety 1998;7:3–14.
2.Turner, JR, Gil, AG.Psychiatric and substance use disorders in South Florida racial/ethnic and gender contrasts in a young adult cohort. Arch Gen Psychiatry 2002;59:43–50.
3.Kessler, RC, Berglund, P, Demler, O, Jin, R, Merikans, KR, Walters, EE.Lifetime prevalence and age-of-onset distributions of DSM-IV disorder in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62: 593–768.
4.Murphy, JM, Laird, NM, Monson, RR, Sobol, AM, Leighton, AH.40-year perspective on the prevalence of depression. The Stirling County Study. Arch Gen Psychiatry 2000;57:209–215.
6.Skolnick, P.Beyond monoamine-based therapies: clues to new approaches. J Clin Psychiatry 2002;63:19–23.
7.Charney, DS.Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998;59:11–14.
8.Castrén, E.Is mood chemistry? Nat Rev Neurosci 2005;6:241–246.
9.Shelton, RC.The molecular neurobiology of depression. Psychiatr Clin N Am 2007;30:1–11.
10.Krishnan, V, Nestler, EJ.The molecular neurobiology of depression. Nature 2008;894–902.
11.Zarate, CA Jr, Singh, JB, Carlson, PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856–64.
12.Millan, MJ.Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135–370.
13.Baghai, TC, Grunze, H, Sartorius, N.Antidepressant medications and other treatments of depressive disorders: a CINP task force report based on a review of evidence. Int J Neuropsychopharmacol 2007;10:S1–S207.
14.Morilak, DA, Frazer, A.Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2007;7:193–218.
15.Johnson, AM.Paroxetine: A pharmacological review. Int Clin Psychopharmacology 1992;6:15–24.
16.Richelson, E.Pharmacology of anti-depressants – characteristics of the ideal drug. Mayo Clin Proc 1999;69: 1069–1081.
17.Duman, RS, Heninger, GR, Nestler, EJ.A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597–606.
18.Calabrese, V, Scapagnini, G, Giuffrida-Stella, AM, Bates, TE, Clark, JB.Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem Res 2001;26: 739–764.
19.Horn, D, Barrientos, A.Mitochondrial copper metabolism and delivery to cytochrome c oxidase. IUBMB Life 2008;60:421–429.
20.Blass, JP.Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 2001;66:851–856.
21.Brennan, WA, Bird, ED, Aprille, JR.Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985;44:1948.
22.Heales, SJ, Bolanõs, JP, Stewart, VC, Brookes, PS, Land, JM, Clark, JB.Nitric oxide, mitochondria and neurological disease. Biochim Biophys Acta 1999;1410:215–228.
23.Schurr, A.Energy metabolism, stress hormones and neural recovery from cerebral ischemia/hypoxia. Neurochem Int 2002;41:1–8.
24.Monsalve, M, Borniquel, S, Valle, I, Lamas, S.Mitochondrial dysfunction in human pathologies. Front Biosci 2007;12:1131–1153.
25.Moreira, PI, Santos, MS, Oliveira, CR.Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid Redox Signal 2007;9:1621–1630.
26.Moreira, PI, Santos, MS, Seiça, R, Oliveira, CR.Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci 2007;257:206–214.
27.Tretter, L, Mayer-Takacs, D, Adam-Vizi, V.The effect of bovine serum albumin on the membrane potential and reactive oxygen species generation in succinate-supported isolated brain mitochondria. Neurochem Int 2007; 50:139–147.
28.Petrosillo, G, Matera, M, Casanova, G, Ruggiero, FM, Paradies, G.Mitochondrial dysfunction in rat brain with aging: involvement of complex I, reactive oxygen species and cardiolipin. Neurochem Int 2008;53:126–131.
29.Kanarik, M, Matrov, D, Kõiv, K, Eller, M, Tõnissaar, M, Harro, J.Changes in regional long-term oxidative metabolism induced by partial serotonergic denervation and chronic variable stress in rat brain. Neurochem Int 2008;52: 432–437.
30.Stanyer, L, Jorgensen, W, Hori, O, Clark, JB, Heales, SJ.Inactivation of brain mitochondrial Lon protease by peroxynitrite precedes electron transport chain dysfunction. Neurochem Int 2008;53:95–101.
31.Nestler, EJ, McMahon, A, Sabban, EL, Tallman, JF, Duman, RS.Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl Acad Sci U S A 1990;87: 7522–7526.
32.Berrocoso, E, Rojas-Corrales, MO, Micó, JA.Non- selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice. Neurosci Lett 2004;363:25–28.
33.Casarotto, PC, Andreatini, R.Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone. Eur Neuropsychopharmacol 2007;17:735–742.
34.Drapier, D, Bentué-Ferrer, D, Laviolle, B, Millet, B, Allain, H, Bourin, M, Reymann, JM.Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze. Behav Brain Res 2007;176:202–209.
35.Ide, S, Fujiwara, S, Fujiwara, M et al. Antidepressant-like effect of venlafaxine is abolished in µ-opioid receptor-knockout mice. J Pharmacol Sci 2010;114:107–110.
36.Lowry, OH, Rosebough, NG, Farr, AL, Randall, RJ.Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
37.Cassina, A, Radi, R.Differential inhibitory Aation of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch Biochem Biophys 1996;328:309–316.
38.Fischer, JC, Ruitenbeek, W, Berden, JA et al. Differential investigation of the capacity of succinate oxidation in human skeletal muscle. Clin Chim Acta 1985;153:23–26.
39.Rustin, P, Chretien, D, Bourgeron, T et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994;228:35–51.
40.Rex, A, Schickert, R, Fink, H.Antidepressant-like effect of nicotinamide adenine dinucleotide in the forced swim test in rats. Pharmacol Biochem Behav 2004;77:303–307.
41.Boekema, EJ, Braun, HP.Supramolecular structure of the mitochondrial oxidative phosphorylation system. J Chem Biol 2007;282:1–4.
42.Fattal, O, Budur, K, Vaughan, AJ, Franco, K.Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006; 47:1–7.
43.Madrigal, JL, Olivenza, R, Moro, M et al. Glutathione depletion, lipid peroxidation and mitochondrial dysfunction are induced by chronic stress in rat brain. Neuropsychopharmacology 2001;24:420–429.
44.Gardner, A, Johansson, A, Wibom, R et al. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord 2003;76:55–68.
45.Gamaro, GD, Streck, EL, Matté, C, Prediger, ME, Wyse, AT, Dalmaz, C.Reduction of hippocampal Na+,K+-ATPase activity in rats subjected to an experimental model of depression. Neurochem Res 2003;28:1339–1344.
46.Rezin, GT, Cardoso, MR, Gonçalves, CL et al. Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem Int 2008;53:395–400.
47.Assis, LC, Rezin, GT, Comim, CM et al. Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats. Rev Bras Psiquiatr 2009;31:247–252.
48.Santos, PM, Scaini, G, Rezin, GT et al. Brain creatine kinase activity is increased by chronic administration of paroxetine. Brain Res Bull 2009;80:327–330.
49.Scaini, G, Santos, PM, Benedet, J et al. Evaluation of Krebs cycle enzymes in the brain of rats after chronic administration of paroxetine. Brain Res Bull 2010;82: 224–227.
50.Consoni, FT, Vital, MA, Andreatini, R.Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test. Eur Neuropsychopharmacol 2006;16:451–458.
51.Krass, M, Wegener, G, Vasar, E, Volke, V.The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011; 218:57–63.
52.Streck, EL, Feier, G, Búrigo, M et al. Effects of electroconvulsive seizures on Na+, K+-ATPase activity in the rat hippocampus. Neurosci Lett 2006;404:254–257.
53.Búrigo, M, Roza, CA, Bassani, C et al. Decreased creatine kinase activity caused by electroconvulsive shock. Neurochem Res 2006;31:877–881.
54.Kálmán, J, Palotás, A, Juhász, A et al. Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression–evolution of antidepressants and the role of the “neuro-immune” system. Neurochem Res 2005;30:1429–1438.
55.Piubelli, C, Gruber, S, El Khoury, A, Mathé, AA, Domenici, E, Carboni, L.Nortriptyline influences protein pathways involved in carbohydrate metabolism and actin-related processes in a rat gene-environment model of depression. Eur Neuropsychopharmacol 2010. [E-pub ahead of print; DOI:10.1016/j.euroneuro.2010.11.003]
56.McHugh, PC, Rogers, GR, Loudon, B, Glubb, DM, Joyce, PR, Kennedy, MA. Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetine. J Neurosci Res 2008;86:306–316.